Gene therapy is an experimental technique that encompasses the replacement of mutated genes with healthy genes. During the treatment of cancer, the genes are replaced to fight against carcinogenic tumor cells. Gene therapy is considered to be an effective treatment for chronic diseases as they cause minimum side effects with maximum efficacy. The global cancer gene therapy market was valued at $289 million in 2016, and is estimated to reach $2,082 million by 2023, registering a CAGR of 32.4% from 2017 to 2023.
The rise in prevalence of cancer, benefits of cancer gene therapy over conventional cancer therapies, and the advancement in this field are the major factors that drive the market growth. In addition, increase in government support, ethical acceptance of gene therapy for cancer treatment, and rise in biotechnological funding encourage the R&D activities for cancer gene therapy and thus fuel the growth of the cancer gene therapy market. However, high cost associated with the treatment and unwanted immune responses are expected to restrain the market growth.
The global cancer gene therapy market is segmented based on therapy, end user, and geography. Based on therapy, it is categorized into gene induced immunotherapy (delivery of cytokines gene and delivery of tumor antigen gene), oncolytic virotherapy (adenovirus, lentivirus, retro virus, adeno associated virus, herpes simplex virus, alpha virus, vaccinia virus, simian virus, and others), and gene transfer (naked plasmid vector, electroporation, sonoportion, magnetofection, and gene gun). Based on geography, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
This report offers a detailed quantitative analysis of the current market trends from 2016 to 2023 to identify the prevailing opportunities.
The market estimations provided in this report are based on comprehensive analysis of the key developments in the industry.
In-depth analysis based on geography facilitates in analyzing the regional market to assist in strategic business planning.
The development strategies adopted by key manufacturers are enlisted in the report to understand the competitive scenario of the market.
KEY PLAYERS PROFILED
Adaptimmune
GlaxoSmithKline
Bluebird bio, Inc.
Merck
Celgene
Shanghai Sunway Biotech
BioCancell
Shenzhen SiBiono GeneTech
SynerGene Therapeutics
OncoGenex Pharmaceuticals
KEY MARKET SEGMENTS
By Therapy
Gene Induced Immunotherapy
Delivery of Cytokines Gene
Delivery of Tumor Antigen Gene
Oncolytic Virotherapy
Adenovirus
Lentivirus
Retro Virus
Adeno Associated Virus
Herpes Simplex Virus
Alpha Virus
Vaccinia Virus
Simian Virus
Others
Gene Transfer
Naked/Plasmid Vectors
Electroporation
Sonoportion
Magnetofection
Gene Gun
By End User
Hospitals
Diagnostics Centers
Research Institutes
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
UK
France
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
Rest of Asia-Pacific
LAMEA
Brazil
Republic of South Africa
Saudi Arabia
Rest of LAMEA
The other players of the cancer gene therapy market include (companies not profiled in the report):
Cell Genesys
Advantagene
GenVec
BioCancell
Celgene and Epeius Biotechnologies
Introgen Therapeutics
Ziopharm Oncology
Shenzhen SiBiono GeneTech
Genelux Corporation
Altor Bioscience
